Shots:

• The P-II (PREVAIL) study will evaluate BNC210 as an acute, or single-dose, treatment for patients with SAD among one of three treatment groups (225 mg BNC210, 675 mg BNC210 or PBO) with ~50 participants in each group
• In Nov 2021, the US FDA cleared the study (PREVAIL) SAD protocol, and a central US IRB granted ethics approval in Dec 2021. Involvement of 15 to 20 US clinical sites are expected in recruiting patients for this study
• The topline results are expected in late-2022 for the (PREVAIL) study and by mid-2023 for the ongoing P-IIb PTSD (ATTUNE) study. BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor

Ref: PR Newswire | Image: Bionomics